Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
31 oct. 2023 03h00 HE
|
Sosei Group Corporation
NDA includes robust data from a Phase 3 trial that demonstrated efficacy of daridorexant on improving Total Sleep Time and Latency for Sleep Onset, while maintaining a favorable safety profileSosei...
Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress
25 oct. 2023 04h00 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 25 October 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Friday, 10 November 2023, at 4 pm JST. The meeting will be held...
Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023
18 oct. 2023 03h04 HE
|
Sosei Group Corporation
Tokyo, Japan, and Cambridge, UK, 18 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused...
Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration
10 oct. 2023 02h30 HE
|
Sosei Group Corporation
The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality novel chemistry...
Sosei Heptares Adds World-leading Expertise to its Scientific Advisory Board
20 sept. 2023 02h30 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 20 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) announces the appointment of four new members to its Scientific Advisory Board (SAB) to advise on...
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
11 sept. 2023 19h01 HE
|
Sosei Group Corporation
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric...
Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732
10 août 2023 02h52 HE
|
Sosei Group Corporation
HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10...
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023
04 août 2023 02h37 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 4 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
Sosei Heptares - Investor and Press Conference on Today’s Announcement Regarding the Acquisition and License Transaction with Idorsia
20 juil. 2023 02h31 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 20 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), will hold an investor and press conference on today’s announcement; “Sosei Heptares Acquires...
Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company
20 juil. 2023 02h30 HE
|
Sosei Group Corporation
Transaction adds complementary late-stage clinical development capability with profitable and fast-growing commercial operations in JapanLean, go-to-market commercial model, well positioned to scale...